Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (391-400 of 436) with videos related to

Pageof 44
Sort By:
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
American Journal of Respiratory Cell and Molecular Biology|October 10, 2025
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor PneumonitisMohammad I Ghanbar, Andres Villabona-Rueda, Nicolas Philip, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Cancer|April 29, 2021
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 44

Showing results (391-400 of 436) with videos related to

Sort By:
Pageof 44
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
American Journal of Respiratory Cell and Molecular Biology|October 10, 2025
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor PneumonitisMohammad I Ghanbar, Andres Villabona-Rueda, Nicolas Philip, et al.
The Lancet. Haematology|November 19, 2022
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Cancer|April 29, 2021
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Pageof 44